BackgroundRight ventricular involvement in ST segment elevation myocardial infarction (STEMI) entails an increased morbidity and mortality. However, very scarce data is present on its affection in the setting of non-ST segment elevation myocardial infarction (NSTEMI).AimTo assess the affection of right ventricular function in patients presenting with NSTEMI undergoing an invasive procedure.Subjects and methodsOne hundred and fifty patients admitted with a first NSTEMI and eligible for reperfusion therapy via invasive percutaneous coronary intervention. These patients were divided in two groups; group A including patients with normal RV function, and group B including patients with impaired RV function as diagnosed by tricuspid annular plane systolic excursion (TAPSE) cutoff value < 17 mm. All patients underwent angioplasty and were followed up in-hospital and for 3 months.ResultsRV dysfunction occurred in ninety-five (61.3%) patients of the study population. Significant improvement occurred to TAPSE after 3 months in comparison to TAPSE at baseline (15.45 ± 3.21 versus 17.09 ± 4.17 mm). Those with impaired RV function showed improvement of TAPSE after three months as compared to baseline (13.62 ± 2.58 vs 17.16 ± 3.64 p = 0.008). Multivariate analysis determined the independent predictors of RV dysfunction as RVEDD > 26 mm, RVFAC < 35%, RAA > 20 cm2, and TAPSE < 17 mm.ConclusionRV dysfunction is not uncommon in NSTEMI when using the definition of TAPSE < 17 mm. Following up RV function by TAPSE, showed significant improvement after 3 months with successful PCI as compared to baseline. We recommend assessing and following up RV function in all patients admitted with a NSTEMI.

Bjerknes and Bomi Framroze. Preliminary Insights into the Inflammation-Resolving Effect of OmeGo, An Enzymatically Liberated Fish Oil, Compared to Diclofenac in A Rat Paw Edema Injection Model. Biomed J Sci & Tech Res 47(1)-2022. BJSTR. MS.ID.007452.Whilst inflammation is a natural response to injury and wear and tear on the body the associated pain and swelling are clearly problematic for the sufferer. Marin polyunsaturated fatty acids, including omega-3, are known to have inflammation-resolving effects and our previous work has shown the minimally processed whole fish oil, OmeGo, to significantly reduce type 2, allergic inflammation. As a next step, this preliminary study used a standard carrageenan-induced rat paw swelling model of (type 1) acute inflammation to assess whether OmeGo could alleviate the paw swelling. Over the 24-hour period of the study, OmeGo showed a similar impact on paw swelling as active control, the non-steroidal anti-inflammatory drug, diclofenac. Diclofenac also markedly reduced the inflammatory cytokines IL-1 and IL-6 whereas OmeGo did not. This suggests that OmeGo's effects occur through different pathways compared to NSIAD therapy. Further work is planned to further characterise OmeGo's modulation of inflammatory pathways and its potential as a pragmatic approach to help resolve acute inflammation.the resulting inflammation compared to diclofenac.